Mechanism of Action
BLASTX uses patented XBIO Technology to attack biofilm structures, removing the metal ions that hold the EPS together. This exposes the bacteria within the biofilm and makes them more vulnerable to attack and eradication. Bacteria that are enveloped within the biofilm disruption technology then experience cell lysis through a high osmolarity imbalance across the bacterial cell membrane and wall. XBIO Technology’s broad-spectrum efficacy helps defend from biofilm reformation.
Studies show BLASTX® provides broad-spectrum efficacy and multi-log microorganism reduction.
Clinical and Scientific Evidence
Serena, T. J., Jalodi, O., Serena, L., Patel, K., Myntti, M., (Jan 2021). Evaluation of the combination of a biofilm-disrupting agent and negative pressure wound therapy: a case series. Journal of Wound Care 30(1), 9-14.
Carter, M. M. (2019). Cost-utility of a biofilm-disrupting gel versus standard of care in chronic wounds: a Markov microsimulation model based on a randomised control trial. Journal of Wound Care North American Supplement 28(7) July, 1-13.
Kim D, Namen W, Moore J, Buchanan M, Hayes V, Myntti M, Hakaim A. Clinical Assessment of a Biofilm-disrupting Agent for the Management of Chronic Wounds Compared With Standard of Care: A Therapeutic Approach. Wounds. Epub 2018.
Snyder RJ, Bohn G, Hanft J, Harkless L, Kim P, Lavery L, Schultz G, Wolcott R. Wound Biofilm: Current Perspectives and Strategies on Biofilm Disruption and Treatments. Wounds: a compendium of clinical research and practice. 2017 Jun;29(6):S1-S17
Miller KG, Tran PL, Haley CL, et al. Next science wound gel technology, a novel agent that inhibits biofilm development by gram-positive and gram-negative wound pathogens. Antimicrob Agents Chemother. 2014;58(6):3060–3072.
The Addition of Antibiofilm Agents to Negative Pressure to Improve Outcomes
Presented by: THOMAS E. SERENA, MD, FACS, FACHM, MAPWCA Founder & CEO SerenaGroup® President – Association for the Advancement of Wound Care (AAWC)